Search Results for: Aurora
Aurora Cannabis Announces Fiscal 2022 Third Quarter Results
Increasing Original Target for Expense Savings; Management Now Expects $150 to $170 Million in Annualized Cost Savings by H1/2023…
Aurora Cannabis to Host Third Quarter Fiscal Year 2022 Investor Conference Call
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining…
Aurora Cannabis Advances Premiumization Strategy by Acquiring Thrive Cannabis, and its Award-Winning Greybeard Brand, in a Margin Accretive Transaction
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining…
Aurora Cannabis Announces Fiscal 2022 Second Quarter Results
Global Cannabis Net Revenue of $60.6 Million Adjusted EBITDA Improved by 22% to a loss of $9.0…
Aurora Cannabis to Host Second Quarter Fiscal Year 2022 Investor Conference Call
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining…
Aurora Cannabis to Host Second Quarter Fiscal Year 2022 Investor Conference Call on Feb. 10
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the…
Aurora Cannabis Delivers ~$10 Million Shipment of Medical Cannabis to Israel
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the…
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”), the Canadian company defining the future of cannabinoids worldwide,…
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
Aurora Cannabis Inc. (NASDAQ | TSX: ACB) (“Aurora”), the Canadian company defining the future of…
Aurora Builds on a Decade of Global Leadership in Plant Genetics with the Launch of Occo
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the…
Recent Comments